Quotient Clinical has been acquired from the Quotient Bioresearch Group by Bridgepoint Development Capital.
Quotient Clinical has been acquired from the Quotient Bioresearch Group by Bridgepoint Development Capital.
Quotient's platform, which "offers an integrated approach to formulation development, 'real-time' drug product manufacturing and clinical testing," has been proven to reduce the time and cost of early stage drug development. A global company, Quotient has two primary facilities in the UK, and more that 3/4 of its revenues are from customers in the US or mainland Europe.
The financial details of the acquisition were undisclosed.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
CAHtalyst Trial Shows Crenessity Sustains Efficacy in Classic Congenital Adrenal Hyperplasia
July 14th 2025Results from the Phase III CAHtalyst show that patients treated with Crenessity for classic congenital adrenal hyperplasia achieved and maintained lower, more physiologic glucocorticoid doses while keeping key adrenal biomarkers at or below baseline levels.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.